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Abstract 
α2,8-linked polysialic acid (polySia) is an 
oncofetal antigen with high abundance during 
embryonic development and reappearance in 
malignant tumors of neuroendocrine origin. 
Responsible for polySia biosynthesis are the two 
polysialyltransferases (polySTs) ST8SiaII & IV. 
During development, both enzymes are essential 
to control polySia expression. However, in the 
tumor situation ST8SiaII is the prevalent enzyme.  
Consequently, ST8SiaII is an attractive target for 
the development of novel cancer therapeutics. A 
major challenge thereby is the high structural and 
functional conservation of  ST8SiaII & IV. To 
search for specific inhibitors an assay system that 
enables differential testing of ST8SiaII & IV 
would be of high value. Here we exploited the 
different modes of acceptor recognition and 
elongation for this purpose. With DMB-DP3 and 
DMB-DP12 (fluorescently labeled sialic acid 
oligomers with a degree of polymerization of 3 
and 12, respectively) we identified stark 
differences between the two enzymes. The new 
acceptors enabled the simple comparative testing 
of the polyST initial transfer rate for a series of 
CMP-activated and N-substituted sialic acid 
derivatives. Of these derivatives, the non-
transferable CMP-Neu5Cyclo was found to be a 
new, competitive ST8SiaII inhibitor. 
Introduction 
In mammals, the term polysialic acid (polySia) is 
used to describe a homopolymer of the negatively 
charged nine-carbon sugar sialic acid (Sia), each 
monomer unit conjugated via an α2,8-glycosidic 
linkage [1]. PolySia is primarily observed as a 
posttranslational modification of the neural cell 
adhesion molecule (NCAM) and has, in numerous 
studies, been demonstrated to regulate cell-cell 
distances and cellular plasticity by physically 
increasing the intercellular space (for review see 
[2]). This function as a mediator of cellular 
plasticity explains the abundance of polySia-
NCAM during mammalian development [3-5]. 
PolySia is gradually reduced during tissue 
maturation [6;7] and becomes virtually undetectable 
in peripheral adult tissues [7]. However, as an 
oncofetal antigen, polySia reappears in a series of 
different tumors (for a review see [8]) and the level 
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of polySia expression in tumors has been 
demonstrated to negatively correlate with patient 
prognosis [9;10]. Similar to its function during 
development, polySia is likely to support 
neoplasia by destabilizing cell-cell contacts and 
promoting cellular motility [11-13]. In addition, 
camouflage with the non-immunogenic polySia 
helps tumor cells to escape immune surveillance 
mechanisms [14]. 
The virtual absence of polySia on adult peripheral 
tissues and its re-appearance on cancer cells makes 
the glycan an attractive target for therapeutic 
approaches and different strategies to realize this 
goal are currently under investigation [8]. For 
example, polySia-specific endosialidases have 
been applied to remove the protecting polySia 
shell from the tumor [15]. Alternatively, metabolic 
labelling strategies have been developed, in which 
the cellular sialylation pathway is hijacked to 
integrate non-natural Sia-derivatives into polySia 
chains with the intention to convert polySia into an 
immunogenic structure (for an extensive review 
see [16]). In order to specifically target 
polysialylation pathways, and avoid sialylation 
pathways which are active in a variety of healthy 
adult cell types, specific polysialyltransferase 
inhibitors are required [8]. Of high importance in 
the search for inhibitors, as well as compounds 
with which polySia can be metabolically labeled, 
is a sensitive method that enables the detailed 
functional evaluation of the mammalian polySTs. 
Mammals encode two polySTs (ST8SiaII and 
ST8SiaIV) [17]. The enzymes share 59% identity at 
the amino acid sequence level and each has been 
demonstrated to independently synthesize polySia 
on NCAM in vitro and in vivo [18;19]. However, 
analyses of animal models with different allelic 
combinations of polySTs demonstrated significant 
differences in the catalytic functions of these 
enzymes. Three findings are of particular interest: 
i) ST8SiaII is the prime enzyme of polySia 
synthesis during development, it is essential to 
guarantee exhaustive polysialylation of the NCAM 
pool [7;20;21]; ii) ST8SiaIV is the major enzyme in 
the adult brain and the polyST-form expressed in 
the scattered peripheral tissues that retain dynamic 
polySia expression in the adult [22-24]; iii) ST8SiaII 
is the predominant enzyme in tumors [25] and thus 
the major target for drug design. Consequently, we 
are searching for test systems that would allow 
identification of the differential effects of 
inhibitors on ST8SiaII and ST8SiaIV activity. 
Recently, we introduced the fluorescent acceptor 
DMB-DP3 (a 1,2-Diamino-4,5-methylendioxy-
benzene-labelled trimer of α2,8-linked sialic acid) 
as a general acceptor for the sensitive and in depth 
kinetic testing of polySTs [8;26]. Of note, this test 
system impressively confirmed data obtained in 
mouse studies by demonstrating that ST8SiaII has 
a much higher capacity to initiate polySia chains 
than ST8SiaIV, the latter preferentially elongating 
primers of a size of >DP10 [26].  
Here we make use of the differential acceptor 
length preferences of human polySTs to advance 
the DMB-acceptor based polyST test system. 
Using DMB-labelled oligo-Sia acceptors of 
different lengths, we have evaluated the activity of 
human polySTs towards CMP-activated and 
N-substituted Sia-derivatives. We discovered an 
inhibitor for ST8SiaII that could serve as a lead 
structure for the development of further improved 
inhibitors. These compounds are of interest as 
potential cancer therapeutics. 
Experimental Procedures 
Reagents 
Chemicals were obtained from Sigma-Aldrich 
(Poole, UK), Sigma-Aldrich (Steinheim, 
Germany), AppliChem (Darmstadt, Germany) or 
Carl Roth (Karlsruhe, Germany) unless otherwise 
stated. The CMP-activated Neu5Ac derivatives 
N-propanoyl neuraminic acid (Neu5Prop), 
N-butanoyl neuraminic acid (Neu5But), 
N-pentanoyl neuraminic acid (Neu5Pent) and 
N-cyclopropylcarbonyl neuraminic acid 
(Neu5Cyclo) were synthesized as previously 
described [27]. Human ST8SiaII and ST8SiaIV 
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were purchased from R&D systems (Minneapolis, 
USA). 
DMB labelling and purification of DMB-
labelled oligosaccharides 
In this study, DMB-DP3 and DMB-DP12 were 
used to prime polyST reactions. The compounds 
were synthesized and isolated according to 
published protocols [26;28-31]. In brief: 25 mg DP3 
(trimer of α2,8-linked Sia) or 100 mg colominic 
acid (α2,8-linked polySia from bacterial source) 
were dissolved at 10 mg/ml in 20 mM DMB with 
1 M β-mercaptoethanol and 40 mM sodium 
dithionite. Solutions were then mixed with equal 
volumes of ice-cold 40 mM trifluoracetic acid 
(TFA) and incubated for 48 h at 4 °C. Reactions 
were terminated by the addition of one fifth 
reaction volume of 200 mM sodium hydroxide. 
Lactonisation of oligo/polySia was reversed by a 
second incubation step at pH 10.0 and 4 °C for 
48 h. For the purification of DMB-DP3 and DMB-
labelled oligo/polySia fragments prepared by this 
procedure from colominc acid, we used anion 
exchange chromatography (MonoQ 10/100 
column, Amersham Bioscience, Amersham, UK). 
50 mM trishydroxymethylaminomethane 
(Tris)/HCl buffer at pH 8.0 without (M1) or with 
1 M sodium chloride (M2) was used as the mobile 
phase. The flow rate was set to 4 ml / min. After 
12 ml of washing with buffer M1, the 
DMB-labelled compounds were eluted with a 
linear sodium chloride gradient as follows: From 0 
to 8 % M2 over 12 ml, from 8 to 20 % M2 over 
56 ml,  from 20 to 45 % M2 over 208 ml. 4 ml 
fractions were collected. Fractions containing 
DMB-DP3 and DMB-DP12, respectively, were 
pooled, desalted via a 2,000 MWCO membrane 
(Satorius, Göttingen, Germany) and concentrated. 
If single DPs were required, isolated pools were 
re-chromatographed using high performance liquid 
chromatography (HPLC; UFLC-RX system, 
Shimadzu, Kyoto, Japan) with a fluorescence 
detector (FD; RF10A XL) and a CarboPac PA-100 
4x250 mm column (Dionex, Sunnyvale, USA). 
Elutions were detected with an excitation 
wavelength of 374 nm and emission at 456 nm. 
Buffers used were 20 mM sodium nitrate (M3) and 
1 M sodium nitrate (M4). Elution was achieved 
with a curved gradient from 0 % to 26 % M4 for 
4.2 ml followed by a linear gradient from 26 % to 
50 % for 9 ml. The flow rate was 0.6 ml/min as 
described [26]. Desalting and concentration of 
samples was as described above. The chain length 
of individual fractions was confirmed by the 
retention time, as described in Keys et al. 2014 [30]. 
In vitro activity testing of polySTs 
Activity testing of human polySTs with different 
donors and acceptors was carried out in test buffer 
(10 mM cacodylate HCl pH 6.7, 20 mM MgCl2, 
10 mM MnCl2, 50 mM KCl and 5 % glycerol). 
The acceptors (DMB-DP3 and DMB-DP12) were 
used at a final concentration of 2.5 µM and 
CMP-Neu5Ac or derivatives thereof at a final 
concentration of 500 µM. ST8SiaII was utilized at 
a concentration of 12.5 µg/ml and ST8SiaIV at 25 
µg/ml. Reactions were incubated at 25°C and 
stopped at distinct time points by the addition of 
four volumes of stop buffer (80 mM Tris/HCl pH8 
containing 16 mM EDTA) and incubation at 50 °C 
for 10 min. Before HPLC-FD analysis, samples 
were centrifuged for 10 min at 20,000 g and 4 °C. 
Supernatants were collected and separated via 
anion exchange chromatography using a 4 x 250 
mm DNAPac PA 100 column (Dionex, Sunnyvale, 
USA) with online UV and fluorescence detection. 
Results were analyzed with empower 2 software 
(Waters, Manchester, UK). Reaction products 
were separated at a flow rate of 1.2 ml/min using 
different ammonium acetate gradients depending 
on the priming acceptor used. If DMB-DP3 was 
used as an acceptor, the gradient consisted of 2 
min water, 7 min linear increase to 185 mM 
NH4OAc). With DMB-DP12 as the acceptor, the 
elution gradient was modified to 10 min linear 
increase of NH4OAc from 350 mM to 425 mM. 
The quantification of substrates and products was 
performed by integrating peaks using empower 2 
software.  
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Measurement of ST8SiaII inhibition 
The Neu5Cyclo concentration required to cause 
half maximum inhibition (Ki) for ST8SiaII was 
determined in an in vitro activity assay with 20 
µM DMB-DP3 and three different CMP-Neu5Ac 
concentrations (50 µM, 100 µM and 150 µM). 
Each condition was tested in triplicate, as a 
minimum, with a series of CMP-Neu5Cyclo 
concentrations from 0 to 10 µM in the described 
buffer. Aliquots of the reactions were collected 
after 30, 60, 120, 180 and 240 min and further 
processed as noted in the previous section. A 
standard curve obtained from a dilution series of 
DMB-DP3 (0 to 10 µM) was used to calculate the 
amount of DMB-DP4 in ng. The first derivatives 
of the polynomial trend lines for the time 
dependent increase of DMB-DP4 were used to 
calculate the initial reaction velocities (v) 
(ng/min/µg enzyme) for each condition. KM of 
CMP-Neu5Ac for ST8SiaII with DMB-DP3 as the 
acceptor was determined by plotting v-1 versus the 
inverse substrate concentration (s-1) in a 
Lineweaver-Burk plot. The intersection of the 
linear regression curve with the x-axis is 
equivalent to -KM-1. To determine the Ki of 
CMP-Neu5Cyclo for ST8SiaII, a Dixon plot of the 
three CMP-Neu5Ac concentrations 50, 100 and 
150 µM was calculated by plotting v-1 against the 
inhibitor concentration. The negative Ki is 
determined from the x-value of the intersection of 
the linear regression curves.  
Results and Discussion 
Analysis of the acceptor preferences of 
ST8SiaII and ST8SiaIV 
When we previously tested mammalian polySTs 
with DMB-DP3, very different patterns of chain 
elongation were observed. ST8SiaII efficiently and 
completely consumed the priming DMB–DP3 to 
produce oligomers with an approximately normal 
distribution around DP7. In contrast, ST8SiaIV 
inefficiently extended the priming structure DMB-
DP3, leaving >10 % unmodified after overnight 
reaction, but efficiently extended the intermediate 
chain lengths to generate long polymers >DP60 
[26]. To further investigate the complimentary 
activity profiles observed for human ST8SiaII and 
ST8SiaIV, we have synthesized and purified 
primers of different length, DMB-DP3 and 
DMB-DP12, to suit each of the enzymes (Scheme 
1). To investigate the preference for specific 
acceptor structures, it was essential to only 
measure the first transfer onto the supplied 
acceptor since each transfer generated a new 
acceptor species with potentially different acceptor 
quality. To achieve this goal we applied optimized 
reaction conditions that result in predominantly 
single transfers, making DMB-DP4 and DMB-
DP13 the major products [32;33]. Preliminary tests 
using equal amounts of the two human polySTs 
showed that the specific activity of ST8SiaIV was 
considerably lower than ST8SiaII. To reach 
conditions that allowed comparative 
measurements, the ST8SiaIV concentration was 
increased by a factor of two in subsequent 
reactions. In a first experiment primed with 
DMB-DP3, the time-course of DMB-DP4 
production was determined. With both polySTs, a 
continuous synthesis of DMB-DP4 over time was 
visible, but with remarkable differences in the 
reaction velocity (Figure 1). Commensurate with 
our previous results, we observed that ST8SiaII 
elongates DMB-DP3 more than 10-fold faster than 
ST8SiaIV. Based on these results, the 4 h time 
point was chosen for subsequent comparisons of 
enzymatic activity.  
We next compared the activity of each enzyme for 
the two different acceptors, DMB-DP3 and DMB-
DP12 (Figure 2). Changing the priming acceptor 
from DMB-DP3 to DMB-DP12 reduced ST8SiaII 
activity by more than 50 % (p = 0.0071 < 0.05 in a 
two-tailed T-test). In sharp contrast, replacement 
of DMB-DP3 by DMB-DP12 in the case of 
ST8SiaIV led to a five-fold increase in activity (p 
= 0.0096 < 0.5 in a two tailed T-test) and thus 
confirmed the increased affinity of ST8SiaIV for 
longer polySia chains. These experiments are the 
first clear demonstration that the two human 
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polySTs have complimentary affinities for polySia 
chains of different length and are in accordance 
with earlier in vivo and in vitro results. Although 
both polySTs can partially compensate for deletion 
of the other polyST, the percentage of 
polysialylated NCAM in vivo is higher when only 
ST8SiaII is expressed than when ST8SiaIV alone 
is present [6]. This observation is further supported 
by the three-fold higher NCAM KM for ST8SiaIV 
than for ST8SiaII and the observation that the 
addition of oligoSia to NCAM leads to an increase 
in ST8SiaIV activity [21;34]. Our in vitro results fit 
perfectly with these studies and provide the 
biochemical basis for these observations, as well 
as the polySia chain length profiles observed in 
mice with genetic deletions of either ST8SiaII or 
ST8SiaIV [6]. Furthermore, the prominent 
difference in acceptor affinity will facilitate an 
improved in vitro analysis of the human polyST 
enzymes and will support the search for specific 
polyST inhibitors as cancer therapeutics.  
Testing of CMP-activated sialic acid derivatives  
With optimized acceptors, DMB-DP3 and DMB-
DP12 for ST8SiaII and ST8SiaIV, respectively, 
we set out to explore differences in activity 
towards CMP-Sia derivatives. We chose a small 
series of Sia-derivatives with substituents of 
increasing size in the 5-N-position of Sia 
(N-propanoyl-, N-butanoyl-, N-pentanoyl- and 
N-cyclopropyl-Sia; Scheme 2). Previous metabolic 
engineering studies using Neu5But and Neu5Pent 
have demonstrated that these derivatives impair 
polysialic acid synthesis by ST8SiaII and 
ST8SiaIV to different extents [35]. Here we applied 
the new assay conditions to address the ability of 
each enzyme to catalyze the transfer of 
5-N-substituted sialic acids from the respective 
CMP-activated sugars. By examining single 
transfers onto the acceptor structure, the results are 
independent of the subsequent effect of these 
modified sugars on acceptor quality. 
We assayed the two polySTs in the presence of 
each acceptor (DMB-DP3 and DMB-DP12) with 
the natural substrate CMP-Neu5Ac and the 
derivatives. ST8SiaII could be assayed effectively 
with DMB-DP3 or DMB-DP12, the inhibitory 
effects of each Sia derivative was independent of 
the specific acceptor used. On the other hand, 
meaningful data for ST8SiaIV was only obtained 
using the longer primer, DMB-DP12, thus 
demonstrating the importance of primer length in 
the search for inhibitors.  
Comparing activities with the natural donor 
substrate we observed that each of the linear acyl 
derivatives exerted a comparable reduction of the 
turnover rate on both enzymes, ranging between 
50 % - 70 % reduced turnover at the 4 h reaction 
time point (Figure 3). In contrast, neither of the 
human enzymes was able to transfer CMP-
Neu5Cyclo and no product was detectable after 4 
h reaction.  
The data obtained here complement results of 
earlier metabolic engineering studies. The study 
by Mahal and colleagues demonstrated that 
N-butanoylmannosamine resulted in a full 
blockade of cellular polysialylation while 
N-propanoylmannosamine had little effect [36]. Our 
results indicate that the blockade of polySia 
synthesis is not due to differences in the transfer of 
these derivatives, but must result from a decrease 
in acceptor quality due to the incorporation of 
derivatives with increasing size of certain N-acyl 
side groups. A study by Horstkorte et al. [35] 
previously indicated that ST8SiaII and ST8SiaIV 
were differentially sensitive to inhibition by the 
N-acyl sialosides (via N-acylmannosamines). 
Based on our results, we can conclude that 
enzyme-specific inhibition is not due to 
differences in nucleotide-sugar binding or sugar 
transfer per se, but results from differences in the 
acceptor binding properties of the two mammalian 
polySTs. This conclusion is supported by in vitro 
experiments using an extracellular domain of 
NCAM with modified glycans as a model acceptor 
substrate [36].  
In contrast to the Sia-derivatives with linear 
substituents, where transfer rates were not reduced 
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below 30 %, CMP-Neu5Cyclo was not transferred 
either by ST8SiaII nor ST8SiaIV. Interestingly, 
this derivative was also unable to be transferred by 
the bacterial polyST from Neisseria meningitidis 
serogroup B [27] despite the fact that these enzymes 
are not homologs, suggesting that the process of 
convergent evolution has brought these enzymes 
not only to catalyze the same reaction but also to 
exhibit similar restrictions towards nucleotide-
sugar substrates. CMP-Neu5Cyclo is the first 
CMP-Sia derivative not to be transferred by the 
mammalian polySTs. To shed more light on this 
finding, we have investigated the inhibitory 
mechanism of CMP-Neu5Cyclo in more detail.  
CMP-Neu5Cyclo is a competitive inhibitor of 
ST8SiaII 
To address the question if CMP-Neu5Cyclo is a 
competitive inhibitor, we measured inhibitor 
kinetics for CMP-Neu5Cyclo. Due to the absence 
of ST8SiaII in the adult brain (polySia expression 
retained in adulthood is synthesized by ST8SiaIV) 
and the dominant role of ST8SiaII in 
polySia-associated tumors, ST8SiaII is perhaps the 
more relevant target for polyST inhibiting anti-
tumor drugs [8]. Consequently, the kinetic data was 
solely measured with human ST8SiaII.  
Activity assays were conducted with constant 
DMB-DP3 and ST8SiaII concentrations and three 
CMP-Neu5Ac concentrations, as well as a series 
of inhibitor concentrations. The time-dependent 
Neu5Ac transfer onto DMB-DP3 was quantified 
using the HPLC-FD activity assay. The initial 
reaction velocities were calculated from the 
time-dependent DMB-DP4 formation. The 
substrate concentration at which the reaction rate 
is half maximal, the Michaelis constant (KM), for 
CMP-Neu5Ac was determined to be 62 µM using 
a Lineweaver-Burk plot (v-1 vs. s-1) (Figure 4A). 
The inhibitor concentration necessary to reduce 
the maximal reaction rate by half, the so-called 
inhibitory constant (Ki), was calculated using a 
Dixon plot, v-1 vs. inhibitor concentration for 
varying substrate concentrations (Figure 4B). This 
analysis revealed that CMP-Neu5Cyclo is a 
competitive inhibitor with a Ki of 25.9 µM ± 0.4 
µM. We conclude that CMP-Neu5Cyclo binds to 
the donor binding site of ST8SiaII, directly 
competing with CMP-Sia. The level of inhibition 
is comparable to that observed for CMP [32;33], 
indicating that Neu5Cyclo does not make a strong 
contribution to binding affinity. However, since 
this substrate is unable to be transferred to 
polySia, it serves as a useful lead compound in the 
search for new anti-cancer therapeutics. In 
combination with the recent structural information 
for ST8Sia-family member, oligosialyltransferase 
ST8SiaIII [37], the development of potent ST8SiaII 
inhibitors as cancer therapeutics can be further 
advanced.  
Conclusion	
In this study we evaluated the acceptor length 
preference for priming the two human polySTs 
ST8SiaII and ST8SiaIV. While ST8SiaII could be 
assayed using the DMB-DP3 acceptor, ST8SiaIV 
activity with this acceptor was too low for reliable 
evaluation of donor sugar analogs. The longer 
DMB-DP12 acceptor is the first fluorescent 
acceptor substrate for investigating inhibition of 
ST8SiaIV activity. 
Using the optimized assay conditions, we studied a 
set of CMP-Sia derivatives that have previously 
been used for metabolic engineering of tumor 
cells. The CMP-activated Sia-derivatives with 
linear acyl substituents, from N-propanoyl to 
N-pentanoyl in position five, were all substrates 
for both of the human polySTs, and were 
transferred at a rate which is 50 % - 70 % slower 
than unmodified Sia. The absence of a significant 
reduction in activity with longer N-substituents 
indicates that the human polySTs do not 
discriminate between these Sia-derivatives. Our 
results provide strong support for the proposition 
that observed differences in the activity of the two 
human polySTs is not due to differences in their 
donor sugar binding but due to dissimilarities in 
their acceptor binding properties [36].  
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Neither of the human polySTs were able to 
transfer the Sia-derivative CMP-Neu5Cyclo. 
Inhibition kinetics for this derivative indicated 
weak, competitive inhibition of ST8SiaII. This 
compound can serve as a lead structure for the 
future development of ST8SiaII inhibitors for 
cancer therapy.  
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Figure Legends 
 
Scheme 1: Chemical structures of the donor and 
acceptor substrates utilized. (A) PolyST acceptor 
DMB‐DP3. (B) PolyST acceptor DMB‐DP12.  
Figure 1: Time course of the polymerisation 
reaction obtained for ST8SiaII (A) and ST8SiaIV (B) 
with DMB‐DP3 and CMP‐Neu5Ac. Measurements 
were performed in triplicate. Depicted are the 
transfers in µM / µg enzyme against the reaction 
time. 
Figure 2: Activity comparison for the two 
acceptors DMB‐DP3 and DMB‐DP12 with the 
human polySTs ST8SiaII and ST8SiaIV. (A) 
Depiction of the transfers of CMP‐Neu5Ac onto 
DMB‐DP3 or DMB‐DP12 by the human polySTs 
ST8SiaII and ST8SiaIV after 4h of reaction time. 
(Significance ** p < 0.01).  
Scheme 2: CMP‐activated 5N‐functionalised sialic 
acid derivatives .  
Figure 3: Comparison of transfers of the 
respective donor sugar derivatives (CMP‐
Neu5Prop, CMP‐Neu5But, CMP‐Neu5Pent and 
CMP‐Neu5Cyclo) onto one of the two acceptors 
DMB‐DP3 and DMB‐DP12 by the human polySTs 
ST8SiaII and ST8SiaIV after 4h reaction. 
Figure 4: Enzyme kinetics of ST8SiaII with the 
inhibitor CMP‐Neu5Cyclo (A) Lineweaver‐Burk 
plot for different donor sugar concentrations. 
Linear regression resulted in the equation y = 
120.9 x +1.95. From the x‐intercept the KM of 
ST8SiaII for CMP‐Neu5Ac was calculated to be 62 
µM. (B) Dixon plot for reactions of ST8SiaII with 
50, 100 and 150 µM donor sugar and a series of 
CMP‐Neu5Cyclo concentrations. The linear 
regression of each series of data is shown as line 
and follows the in Table 1 noted formula. The 
equation of the linear regression resulted in a Ki 
of 25.9 µM ± 0.4 µM.  
 
Table‐of‐Contents  
Two polysialyltransferases (polySTs; ST8SiaII & IV) 
control polysialylation in humans, but ST8SiaII is 
predominant in tumors. Here we exploited 
differences in the preference for priming 
polysialic acid to develop a fluorescent assay with 
which polySTs can be differentiated in inhibitor 
screens.  We describe CMP‐Neu5Cyclo as a first 
hit, competitive polyST inhibitor. 
Tables 
Table 1: Formulae of the linear regression curves 
of the Dixon plot. 
Donor sugar 
concentration 
Equation of the linear 
regression curve 
50 µM y = 0.1524 x + 4.317 
100 µM y = 0.1204 x +3.472 
150 µM y = 0.08462 x + 2.566 
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